You can find the annual or quarterly income statement of Telomir Pharmaceuticals Inc here for insights into the performance and operational efficiency of Telomir Pharmaceuticals Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
Total revenue
----
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Revenue
----
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Operating expenses
-65.19%1.76M
-52.40%1.04M
-26.53%2.13M
-80.91%1.15M
243.84%5.07M
14.18%2.19M
169.36%2.91M
529.48%6.01M
3.38%1.47M
296.75%1.92M
121.44%1.08M
308.64%954.15K
1935.76%1.43M
660.65%482.94K
--487.10K
--233.50K
--70.06K
--63.49K
R&D expenses
938.01%444.67K
38.81%467.80K
381.71%1.30M
21.05%759.52K
-92.80%42.84K
-58.09%337.00K
32.04%269.08K
138.97%627.43K
-10.91%594.80K
82.59%804.02K
-57.31%203.78K
14.28%262.56K
906.76%667.63K
635.85%440.33K
--477.31K
--229.75K
--66.31K
--59.84K
Operating profit
----
52.40%-1.04M
26.53%-2.13M
80.91%-1.15M
-243.84%-5.07M
-14.18%-2.19M
-169.36%-2.91M
-529.48%-6.01M
-3.38%-1.47M
-296.75%-1.92M
-121.44%-1.08M
-308.64%-954.15K
-1935.76%-1.43M
-660.65%-482.94K
---487.10K
---233.50K
---70.06K
---63.49K
Net non-operating interest income (expenses)
Non-operating interest income
3290.31%46.18K
--51.64K
940.61%73.49K
186.06%44.18K
-94.66%1.36K
----
--7.06K
--15.45K
--25.49K
----
----
----
----
----
----
----
----
----
Non-operating interest expense
125.63%3.03K
--1.25K
----
--0.00
--1.34K
----
-100.00%1.00
-100.00%0.00
-100.00%0.00
--4.34M
--761.82K
--757.17K
--124.05K
--0.00
----
--0.00
--0.00
--0.00
Special income (expenses)
----
----
----
----
----
----
----
----
----
----
---7.49M
----
----
----
----
----
----
----
Other non-operating income (expenses)
----
----
----
----
----
----
--1.00
----
----
----
----
----
----
----
----
----
----
----
Income before tax
----
54.54%-990.95K
28.88%-2.06M
81.60%-1.10M
-249.89%-5.07M
65.15%-2.18M
68.93%-2.90M
-250.06%-5.99M
6.54%-1.45M
-1195.12%-6.25M
-1814.86%-9.33M
-632.91%-1.71M
-2112.81%-1.55M
-660.65%-482.94K
---487.10K
---233.50K
---70.06K
---63.49K
Income tax
----
----
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income after tax
----
54.54%-990.95K
28.88%-2.06M
81.60%-1.10M
-249.89%-5.07M
65.15%-2.18M
68.93%-2.90M
-250.06%-5.99M
6.54%-1.45M
-1195.12%-6.25M
-1814.86%-9.33M
-632.91%-1.71M
-2112.81%-1.55M
-660.65%-482.94K
---487.10K
---233.50K
---70.06K
---63.49K
Net income from continuous operations
-1753.08%-93.95M
54.54%-990.95K
28.88%-2.06M
81.60%-1.10M
-249.89%-5.07M
65.15%-2.18M
68.93%-2.90M
-250.06%-5.99M
6.54%-1.45M
-1195.12%-6.25M
-1814.86%-9.33M
-632.91%-1.71M
-2112.81%-1.55M
-660.65%-482.94K
---487.10K
---233.50K
---70.06K
---63.49K
Net income attributable to controlling interests
-843.52%-47.84M
54.54%-990.95K
28.88%-2.06M
81.60%-1.10M
-249.89%-5.07M
65.15%-2.18M
68.93%-2.90M
-250.06%-5.99M
6.54%-1.45M
-1195.12%-6.25M
-1814.86%-9.33M
-632.91%-1.71M
-2112.81%-1.55M
-660.65%-482.94K
---487.10K
---233.50K
---70.06K
---63.49K
Preferred share dividend
---46.11M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Net income attributable to common shareholders
-843.52%-47.84M
54.54%-990.95K
28.88%-2.06M
81.60%-1.10M
-249.89%-5.07M
65.15%-2.18M
68.93%-2.90M
-250.06%-5.99M
6.54%-1.45M
-1195.12%-6.25M
-1814.86%-9.33M
-632.91%-1.71M
-2112.81%-1.55M
-660.65%-482.94K
---487.10K
---233.50K
---70.06K
---63.49K
Basic earnings per share
-365.42%-0.79
60.65%-0.03
37.02%-0.06
83.19%-0.03
-245.20%-0.17
67.48%-0.07
72.36%-0.10
-250.03%-0.20
6.53%-0.05
-1280.99%-0.23
-2048.94%-0.35
-632.57%-0.06
-2109.28%-0.05
-662.15%-0.02
---0.02
---0.01
--0.00
--0.00
Diluted earnings per share
-365.42%-0.79
60.65%-0.03
37.02%-0.06
83.19%-0.03
-245.20%-0.17
67.48%-0.07
72.36%-0.10
-250.03%-0.20
6.53%-0.05
-1280.99%-0.23
-2048.94%-0.35
-632.57%-0.06
-2109.28%-0.05
-662.15%-0.02
---0.02
---0.01
--0.00
--0.00
Dividend per share
----
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
FAQs
How do I read Telomir Pharmaceuticals Inc's income statement on TradingKey?
Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.
What is the difference between quarterly and annual income statements?
A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.
What does YOY mean on the income statement page?
YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.
Which income statement metrics matter most when analyzing TELO stock?
Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.
What was Telomir Pharmaceuticals Inc's net income for the year?
Telomir Pharmaceuticals Inc posted -10.41M in net income for fiscal year 2025.
How much net income did Telomir Pharmaceuticals Inc post in the last quarter?
Telomir Pharmaceuticals Inc reported -47.84M in net income for the latest quarter。
What was Telomir Pharmaceuticals Inc's annual operating profit?
Telomir Pharmaceuticals Inc's operating income was -10.34M for fiscal year 2025.
How is EPS related to the income statement?
EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.